| 词条 | Deferiprone |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443270530 | IUPAC_name = 3-hydroxy-1,2-dimethylpyridin-4(1H)-one | image = Deferiprone.svg | width = 120 | tradename = Ferriprox | Drugs.com = {{drugs.com|international|deferiprone}} | licence_EU = yes | licence_US = Deferiprone | pregnancy_AU = | pregnancy_US = D | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Oral | bioavailability = | protein_bound = | metabolism = Glucuronidation | elimination_half-life = 2 to 3 hours | excretion = Renal (75 to 90% in 24 hours) | IUPHAR_ligand = 7456 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 30652-11-0 | ATC_prefix = V03 | ATC_suffix = AC02 | PubChem = 2972 | ChEBI_Ref = {{ebicite|changed|EBI}} | ChEBI = 68554 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 2866 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 2BTY8KH53L | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D07416 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 70927 | C=7 | H=9 | N=1 | O=2 | molecular_weight = 139.152 g/mol | smiles = O=C\\1C(\\O)=C(/N(/C=C/1)C)C | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = TZXKOCQBRNJULO-UHFFFAOYSA-N }}Deferiprone (tradenames include Ferriprox) is a drug that chelates iron and is used to treat iron overload in thalassaemia major.[1] It was first approved for use in treating thalassaemia major in 1994[2] and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States.[1] On October 14, 2011, it was approved for use in the US under the FDA's accelerated approval program.[3] ControversyDeferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and the pharmaceutical company Apotex, that started in 1996 and delayed approval of the drug in North America.[4] Olivieri's data suggested deferiprone leads to progressive hepatic fibrosis.[5][6][7] See also
References1. ^1 {{cite journal |doi=10.1136/bmj.328.7436.358 |pmid=14962851 |pmc=341373 |title=Thalassaemia major: The murky story of deferiprone |journal=BMJ |volume=328 |issue=7436 |pages=358–9 |year=2004 |last1=Savulescu |first1=J }} {{Chelating agents}}2. ^Staff, Cipla. Cipla's History 3. ^FDA NEWS RELEASE: FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body, Oct. 14, 2011 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm 4. ^{{cite journal |doi=10.1136/jme.2003.006577 |pmid=14872065 |pmc=1757126 |title=Introduction to the Olivieri symposium |journal=Journal of Medical Ethics |volume=30 |issue=1 |pages=1–7 |year=2004 |last1=Viens |first1=A M |last2=Savulescu |first2=J }} 5. ^{{cite journal |doi=10.1182/blood-2002-10-3173 |pmid=12788794 |title=Deferiprone and hepatic fibrosis |journal=Blood |volume=101 |issue=12 |pages=5089–90; author reply 5090–1 |year=2003 |last1=Brittenham |first1=G. M |last2=Nathan |first2=D. G |last3=Olivieri |first3=N. F |last4=Porter |first4=J. B |last5=Pippard |first5=M |last6=Vichinsky |first6=E. P |last7=Weatherall |first7=D. J }} 6. ^{{cite journal |doi=10.1182/blood-2002-01-0306 |pmid=12176871 |title=Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia |journal=Blood |volume=100 |issue=5 |pages=1566–9 |year=2002 |last1=Wanless |first1=I. R |last2=Sweeney |first2=G |last3=Dhillon |first3=A. P |last4=Guido |first4=M |last5=Piga |first5=A |last6=Galanello |first6=R |last7=Gamberini |first7=M. R |last8=Schwartz |first8=E |last9=Cohen |first9=A. R }} 7. ^{{Cite web|url=https://www.thestar.com/news/investigations/2019/02/27/uhn-patients-given-unlicensed-drug-that-led-to-diabetes-liver-dysfunction-and-one-death-study-finds.html|title=UHN patients given unlicensed drug that led to diabetes, liver dysfunction and one death, study finds |work=The Star|location=Toronto|first=Robert |last=Cribb |date=2019-02-27 |language=en|access-date=2019-02-27}} 4 : Chelating agents|Chelating agents used as drugs|Antidotes|4-Pyridones |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。